Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 4282-4288, August 1, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waalkes, M. P.
Right arrow Articles by Henneman, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waalkes, M. P.
Right arrow Articles by Henneman, J. R.

Cadmium Carcinogenesis in Male Wistar [Crl:(WI)BR] Rats: Dose-Response Analysis of Effects of Zinc on Tumor Induction in the Prostate, in the Testes, and at the Injection Site

Michael P. Waalkes1, Sabine Rehm, Charles W. Riggs, Robert M. Bare, Deborah E. Devor2, Lionel A. Poirier3, Martin L. Wenk and John R. Henneman4

Inorganic Carcinogenesis and Tumor Pathology and Pathogenesis Sections, Laboratory of Comparative Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, Frederick, Maryland [M. P. W., S. R., R. M. B., L. A. P.]; Data Management Services, Frederick Cancer Research Facility, Frederick, Maryland [C. W. R.]; and Microbiological Associates, Inc., Bethesda, Maryland [D. E. D., M. L. W., J. R. H.]

The ability of zinc acetate to modify the carcinogenic effects of CdCl2 in male Wistar [Crl:(WI)BR] rats was studied over a 2-year period. Groups of rats received a single s.c. injection of Cd (30.0 µmol/kg) in the dorsal thoracic midline or i.m. in the right thigh at time 0. Zinc was given in three separate s.c. doses of 0.1, 0.3, or 1.0 mmol/kg (at -6, 0, and +18 h relative to cadmium) in the lumbosacral area or p.o. at 100 ppm in the drinking water (-2 to +100 weeks). Cadmium treatments (s.c.) resulted in the appearance of tumors at the injection site and in the testes. The incidence of s.c. injection site tumors (mostly mixed sarcomas) was markedly reduced by high dose (1.0 mmol/kg) s.c. zinc (50% reduction) and was almost abolished by p.o. zinc (92% reduction). Testicular tumors (mostly Leydig cell adenomas) induced by s.c. cadmium were reduced in a dose-related fashion by zinc and were found to be highly dependent on the ability of zinc to prevent the chronic degenerative effects of cadmium in the testes. Oral zinc had no effect on s.c. cadmium-induced testicular tumors, while i.m. cadmium alone did not induce these tumors. In rats in which s.c. cadmium-induced testicular tumors and chronic degenerative effects were prevented by zinc (1.0 mmol/kg, s.c.), a marked elevation in prostatic tumors (exclusively adenomas) occurred (control, 9.6%; cadmium plus high zinc, 29.6%). Cadmium given i.m., which did not result in testicular tumors or degeneration, also induced an elevated incidence (42.3%) of prostatic tumors, again indicating a dependence on testicular function. Prostatic tumor incidence was also significantly elevated (25.0%) in rats receiving 1.0 mmol/kg zinc, s.c., in combination with i.m. cadmium. These results indicate that zinc inhibition of cadmium carcinogenesis is a complex phenomenon, depending not only on dose and route but also on the target site in question.

1 To whom requests for reprints should be addressed, at Laboratory of Comparative Carcinogenesis, NCI-FCRF, Building 538, Room 205E, Frederick, MD 21701.

2 Present address: Laboratory of Comparative Carcinogenesis, NCI-FCRF, Frederick, MD 21701.

3 Present address: Division of Chemical Toxicology, NCTR, Building 15, Jefferson, AR 27079.

4 Present address: Biological Carcinogenesis Development Program, Program Resources, Inc., NCI-FCRF, Frederick, MD 21701.

Received 11/16/88. Revised 4/ 6/89. Accepted 5/ 3/89.




This article has been cited by other articles:


Home page
Toxicol Ind HealthHome page
N. Roney, M. Osier, S. J. Paikoff, C. V. Smith, M. Williams, and C. T. De Rosa
ATSDR evaluation of the health effects of zinc and relevance to public health
Toxicology and Industrial Health, January 1, 2006; 22(10): 423 - 493.
[Abstract] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
M. C. Bosland
Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis
J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. P. Waalkes, S. Rehm, and M. G. Cherian
Repeated Cadmium Exposures Enhance the Malignant Progression of Ensuing Tumors in Rats
Toxicol. Sci., March 1, 2000; 54(1): 110 - 120.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. G. Schwartz and I. M. Reis
Is Cadmium a Cause of Human Pancreatic Cancer?
Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 139 - 145.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.